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Abstract: Aims: Aortic valve sclerosis (AVSc), a non-uniform thickening of leaflets with an unrestricted
opening, is characterized by inflammation, lipoprotein deposition, and matrix degradation. In the
general population, AVSc predicts long-term cardiovascular mortality (+50%) even after adjustment for
vascular risk factors and clinical atherosclerosis. We have hypothesized that AVSc is a risk-multiplier
able to predict even short-term mortality. To address this issue, we retrospectively analyzed 90-day
mortality of all patients who underwent isolated coronary artery bypass grafting (CABG) at Centro
Cardiologico Monzino over a ten-year period (2006–2016). Methods: We analyzed 2246 patients
and 90-day all-cause mortality was 1.5% (31 deaths). We selected only patients deceased from
cardiac causes (n = 29) and compared to alive patients (n = 2215). A cardiologist classified the aortic
valve as no-AVSc (n = 1352) or AVSc (n = 892). Cox linear regression and integrated discrimination
improvement (IDI) analyses were used to evaluate AVSc in predicting 90-day mortality. Results: AVSc
90-day survival (97.6%) was lower than in no-AVSc (99.4%; p < 0.0001) with a hazard ratio (HR) of 4.0
(95%CI: 1.78, 9.05; p < 0.0001). The HR for AVSc, adjusted for propensity score, was 2.7 (95%CI: 1.17,
6.23; p = 0.02) and IDI statistics confirmed that AVSc significantly adds (p < 0.001) to the identification
of high-risk patients than EuroSCORE II alone. Conclusion: Our data supports the hypothesis that a
risk stratification strategy based on AVSc, added to ESII, may allow better recognition of patients at
high-risk of short-term mortality after isolated surgical myocardial revascularization. Results from
this study warrant further confirmation.
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1. Introduction
Aortic valve sclerosis (AVSc) is a non-uniform thickening of valve leaflets with an unrestricted
opening [1]. Based on the American Heart Association (AHA) and the American College of Cardiology
(ACC) guidelines [2], AVSc does not compromise hemodynamics, having a maximal transvalvular
velocity <2.5 m/s on Doppler echocardiographic measurement. This abnormality occurs in 30% of
people who are older than 65 years of age and in more than 40% who are older than 75 years of age [3].
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AVSc is characterized by inflammation, endothelial damage, lipid infiltration, and oxidation,
with direct consequences on extracellular matrix degradation and calcification [4]. AVSc correlates with
vascular risk factors (VRFs), subclinical atherosclerosis, and coronary artery disease and it is considered
an atherosclerosis-like process [1,5]. In the general population, AVSc predicts ventricular hypertrophy
and arrhythmias, myocardial infarction, stroke, and long-term cardiovascular (CV) mortality even
after adjustment for VRFs and clinical atherosclerosis [6,7].
One of the models to estimate the risk of complications (e.g., mortality) after cardiac surgery is
the EuroSCORE II (ESII); an algorithm that allows the evaluation of patient’s surgical candidacy and
treatment selection [8]. In this study, we hypothesized that AVSc, in addition to ESII, behaves as a
risk-multiplier, predicting mortality in patients with an overt atherosclerotic disease requiring coronary
artery bypass grafting (CABG).
Thus, we have recorded 90-day mortality of consecutive patients who underwent isolated CABG
at Centro Cardiologico Monzino, over a period of ten years, to assess whether AVSc is independently
associated with CV mortality after isolated CABG.
2. Methods
2.1. Patients
This observational study was approved by the Institutional Review Board and by the Ethical
Committee of Centro Cardiologico Monzino (CCM, University Hospital). The investigation conforms
to the principles outlined in the Declaration of Helsinki (1964).
All patients who underwent isolated CABG from 2004 to 2015, at Centro Cardiologico
Monzino, were included into this study. Demographic information, preoperative, intraoperative,
and postoperative data were retrieved from the institutional database. The number of anastomosis,
the on- or off-pump technique, as well as the graft used (e.g., saphenous vein, radial artery,
and/or internal thoracic artery) were chosen by staff surgeons according to European guidelines [9].
A total of 2246 patients were identified. At the 90th day post-surgery, 2215 patients were still alive,
whereas 31 were deceased (all-cause mortality: 1.5%). Deceased patients were eligible for the study
only if the cause of death was cardiac (n = 29), their echocardiographic images were of good quality
and they have no sign of significant valve pathologies (e.g., aortic valve stenosis, mitral regurgitation,
or rheumatic heart disease). Therefore, the final analysis included 2244 patients. The flow chart with
patient’s selection is shown in Figure 1.
Figure 1. Case study selection.
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2.2. Echocardiographic Evaluation
Patients referred to CABG undergo mandatory preoperative echocardiographic evaluation [9].
Experienced cardiologists of Centro Cardiologico Monzino performed the echocardiographic scans,
according to the current guidelines [10,11]. The morphology and function of the aortic valve were
assessed to evaluate the presence of AVSc. The AVSc was identified according to criteria described by
Otto et al. [4]; i.e., non-uniform thickening or spotty calcified areas of the aortic valve leaflets without a
significant transvalvular gradient (maximum aortic velocity <2.5 m/s). An expert cardiologist (P.G.)
retrospectively evaluated the images blindly and, in case of uncertainty, another expert (M.P.) evaluated
the echocardiographic scans. The agreement of the AVSc evaluation between the cardiologist who
reassessed the images and the clinical records resulted in a weighted Cohen’s K = 0.88 (p < 0.0001).
2.3. Statistical Analysis
Quantitative variables with normal or skewed distribution were reported as mean ± SD or median
and interquartile range, respectively. Categorical variables were reported as frequency and percentage.
Group comparisons for normal, skewed, and categorical variables were performed by Student t-test for
independent samples, by Wilcoxon rank-sum test, and χ2 test, respectively. The association between
AVSc and 90-day mortality was assessed by Kaplan-Meier survival curves with log-rank test and by
multivariable Cox regression analysis.
Three Cox models were implemented: (1) unadjusted; (2) adjusted for ESII; and (3) adjusted
for a propensity score. The propensity score was computed, by logistic regression analysis, as the
conditional probability of AVSc presence, given the following covariates: age, sex, body mass
index, ejection fraction (EF), diabetes, dyslipidemia, hypertension, previous myocardial infarction,
number of diseased coronaries, NYHA class, ESII, cardiopulmonary bypass (CPB), time on CPB,
need of transfusion, and year of the intervention. In a sensitivity analysis, we also ran a Cox model
adjusted for all the variables significantly associated with AVSc, even if the number of observed events
would allow a maximum of two to three covariates in the model.
To assess whether AVSc adds to prediction of short-term mortality on top of ESII the integrated
discriminating improvement (IDI) index was employed.
3. Results
The examined population was predominantly of male sex (84%) with an average age of 67 years
and medium-low risk (ESII: 1.8 [95%CI: 1.1; 3.6]). Most patients (77%) had a three-vessel coronary
disease with a mean left ventricular EF of 57%.
Among patients enrolled in the study who met the inclusion criteria (n = 2244), 1352 had normal
aortic valve leaflets and were classified as no-AVSc and the remaining 892 (39.8%) had non-uniform
thickening of the aortic leaflets and were classified as AVSc.
Table 1 shows the characteristics of patients with and without AVSc. The groups significantly
differed for age, sex, prevalence of diabetes, NYHA class, EF, CBP and clamping time, and number
of transfused units per patient. No differences were observed in terms of CAD severity, with the
exception of the circumflex artery, which shows an increased number of patients with a stenosis >50%
in the AVSc group. Kaplan-Meier cumulative incidence curves, stratified by presence/absence of AVSc,
showed a significant increase in short-term mortality in AVSc patients (Figure 2).
After 90 days from CABG, the mortality rate in AVSc patients was 2.6% compared to 0.6% in
no-AVSc patients. The unadjusted hazard ratio (HR) was 4.0 (95%CI: 1.78, 9.05; p = 0.0008), the ESII
adjusted HR was 2.9 (95%CI: 1.26, 6.56; p = 0.01), while the propensity score adjusted HR was 2.7
(95%CI: 1.17, 6.23; p = 0.02). In the sensitivity analysis, the adjusted HR was minimally changed (HR:
2.44, 95%CI: 1.03, 5.77; p = 0.04).
In the IDI analysis, the model including AVSc and ESII performed better than the model including
only ESII (IDI = 0.009, 95%CI: 0.004, 0.013; p < 0.001).
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Table 1. Demographic and clinical characteristics of patients deceased within 90 days from
the intervention.
Variables AVSc (n = 892) No-AVSc (n = 1352) p-Value
Age, years 69.4 ± 7.8 64.7 ± 9.1 <0.0001
Male n, (%) 708 (79.4) 1174 (86.8) <0.0001
Body mass index, kg/m2 26.6 ± 3.5 26.8 ± 3.7 0.25
Diabetes mellitus n, (%) 298 (33.4) 367 (27.1) 0.0001
Hypertension n, (%) 668 (74.9) 989 (73.2) 0.36
Dyslipidemia n, (%) 628 (70.4) 1002 (74.1) 0.053
Current smoking n, (%) 147 (27.3) 246 (28.6) 0.84
NYHA heart failure class n, (%)
0.002
I 133 (15.7) 257 (19.9)
II 523 (61.8) 811 (62.9)
III 162 (19.2) 175 (13.6)
IV 28 (3.3) 46 (3.6)
CAD severity
0.23
1-Vessel coronary disease n, (%) 102 (11.4) 166 (12.3)
2-Vessel coronary disease n, (%) 157 (17.6) 272 (20.1)
3-Vessel coronary disease n, (%) 633 (71.0) 914 (67.6)
Arteries with a stenosis ≥50%
Long common trunk n, (%) 249 (27.9) 351 (26) 0.31
Anterior interventricular artery n, (%) 821 (92) 1234 (91.3) 0.52
Circumflex artery n, (%) 760 (85.2) 1104 (81.7) 0.03
Right coronary artery n, (%) 667 (74.8) 1006 (74.4) 0.84
Left ventricular ejection fraction, % 56.3 ± 10.6 57.9 ± 10.0 0.0008
Previous myocardial infarction n, (%) 364 (40.8) 506 (37.4) 0.11
CPB n, (%) 787 (88.2) 1219 (90.2) 0.15
CPB time, minutes 85.2 ± 41.4 90.8 ± 40.7 0.002
Clamping time, min 66.3 ± 22.6 70.3 ± 23.1 0.0002
Number of transfused units per patients, (interquartile range) 2 (0; 2) 0 (0; 2) <0.0001
EuroSCORE II, (interquartile range) 1.6 (0.9; 3) 2.4 (1.3; 4.3) <0.0001
AVSc, aortic valve sclerosis; NYHA, New York Heart Association; CAD, coronary artery disease; CPB,
cardiopulmonary bypass.
Figure 2. Kaplan-Meier cumulative incidence of patients that underwent surgical myocardial
revascularization. (A) unadjusted and (B) adjusted for propensity score survival curves. Patients are
stratified accordingly to normal aortic valve morphology (no-AVSc) or to aortic valve sclerosis (AVSc).
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4. Discussion
In this study, we show for the first time that AVSc is an independent predictor of short-term (90-day)
mortality after isolated surgical myocardial revascularization. The presence of AVSc, as identified in
the routine screening before CABG, increases the risk of postoperative short-term mortality of more
than two folds, and AVSc significantly adds to the identification of patients at high-risk for short-term
mortality compared to EuroSCORE II alone.
Being adjusted for propensity score, our findings suggest: first, that the differences observed are
not due to a simple unbalance of confounding factors in the two groups and second that AVSc probably
reflects a pathophysiological mechanism that it is not fully explained by factors included in the current
version of ESII.
To date, few studies have attempted to define the role of AVSc as a predictor of postoperative
short-term and/or long-term outcomes. Cai et al. [12] reported a significant association between
the presence of AVSc and post-operative major adverse cardiac events (which also included cardiac
death) in 185 renal transplant recipients followed-up for a mean of 60 months; in such study, however,
the short-term mortality was not considered. By contrast, in another study, the prognostic implications
of AVSc on both post-operative short-term (30-day) and long-term composite outcomes were tested in
1172 patients with peripheral arterial disease requiring vascular surgery [13]. In multivariable regression
analysis adjusted for age, gender, revised cardiac risk index, hypertension, hypercholesterolemia,
and medication use, AVSc was not associated with either post-operative or long-term outcomes.
According to these authors, the effect of AVSc was probably attenuated because their cohort was
constituted by vascular surgery patients with extensive multi-vascular disease [13].
In the general population, AVSc is a rather common feature, with a prevalence ranging from 30
to 40% [1,3,13] and AVSc has been associated with an increased risk of all-cause and CV mortality
in many [5,6,14–19] but not all [20] studies. Several authors have shown that the risk of dying from
any-cause or for CV reasons in subjects with AVSc is significantly greater than in those without,
even after adjustment for several risk factors [6,14,21]. Other authors, however, have shown that
such increased-risk is totally eliminated when analyses were adjusted for CV risk factors [20]. AVSc,
alone or included into cardiac calcium scores, also confers a greater risk of all-cause and CV mortality
in subjects with no history of CV disease [14], in subjects with type 2 diabetes mellitus with or without
history of myocardial infarction [16], and in patients hospitalized for overt or suspected CAD [22].
A recent meta-analysis reported a low (but still present) risk of all-cause and CV mortality in patients
with AVSc [23]. Coffey et al. [18] hypothesized that the relatively high baseline risk of patients included
in the study has masked the additional risk due to AVSc. This hypothesis, however, was contrasted
by the results of the Cardiovascular Health Study, an observational cohort study of 3782 elderly
patients followed up for 5 [6] or 6.6 [15] years, where AVSc remained an independent predictor of both
all-cause and CV mortality regardless the presence/absence of baseline CAD. Our data, documenting an
increased risk of mortality in patients who underwent CABG, adds another piece of information to
this controversy.
Despite all the evidence reported in the literature documenting AVSc as a risk-multiplier, its capacity
to act additively or synergistically to ESII for prediction of short-term mortality after CABG has never
been tested. Our findings, showing (a) that AVSc predicts short-term CV mortality independently from
ESII and (b) that AVSc adds to the identification of high-risk patients compared to ESII, strongly endorse
AVSc as a promising factor to be integrated with the approaches currently used for the recognition of
patients who are at high-risk of complications after isolated CABG.
4.1. Clinical Relevance
The identification of new risk factors for peri- and post-operative mortality is a core issue for
guaranteeing high-quality results in risk-scoring systems. Several studies have reported a progressive
worsening of the ESII model performances when applied to follow-up longer than 30 days [24].
In particular for isolated CABG surgeries, a poor calibration of ESII, in both the highest and lowest
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risk-patient groups, was reported [25]. To the best of our knowledge, our study is the first showing that
AVSc could be combined with ESII to improve the identification of patients at high-risk of short-term
mortality after CABG. Another point of relevance that deserves to be highlighted is that the detection of
AVSc used for risk-prediction does not add any additional cost to usual clinical care, as the pre-operative
echocardiography assessment is already mandatory in the evaluation of patients requiring cardiac
surgery [9].
4.2. Strengths and Limitations
Keeping in mind its retrospective nature, our study has several strengths. First, is the tight
control of the methodology for image acquisition and AVSc detection (all echocardiographic scans
have been performed using the same protocol and all the scans were re-read blindly by a single reader
with extensive experience). Second, the level of agreement of AVSc assessment among readers was
strong [26] (Cohen’s Kappa = 0.88) even if derived from scans obtained from clinical practice. Finally,
analyses were adjusted for operation related confounders (e.g., CBP time, transfusions, and year of
intervention) that might have influenced the results. The study has also potential limitations. First,
even if our analyses were performed on a large cohort, the number of events (i.e., mortality) recorded
is small. Nevertheless, our results reach a statistically significant level. Second, our analysis was based
only on a sample of CABG patients so, some caution must be applied before generalizing our results to
other type of patients. Third, we could not distinguish CABG performed with or without CPB, due to
the exiguity of the samples (dead patients with no CPB n = 1). However, the exclusion of the no CPB
patient did not affect the results.
In conclusion, our data supports the hypothesis that a risk stratification strategy based on AVSc,
added to ESII, may allow better recognition of patients at high-risk of short-term mortality after isolated
surgical myocardial revascularization. Results from this study warrant further confirmation.
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